• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Cellectis S.A. (Amendment)

    2/14/24 2:24:22 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLLS alert in real time by email
    SC 13G/A 1 cellectisschedule13gaexitf.htm SC 13G/A CELLECTIS Document


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     

    SCHEDULE 13G 
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1 – Exit Filing)*

    CELLECTIS S.A.

    (Name of Issuer)


    Ordinary Shares, €0.05 nominal value per share
    (Title of Class of Securities)

    15117K103
    (CUSIP Number)

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule
    is filed:


    |X| Rule 13d-1(b)
    |   | Rule 13d-1(c)
    |   | Rule 13d-1(d)


    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     
     

     




     
    Page 1 of 6

    CUSIP No. 15117K103

    1.Names of Reporting Persons. PFIZER INC. 13-5315170
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)
    ☐
    (b)
    ☐
    3.SEC Use Only
    4.Citizenship or Place of Organization: Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON WITH:
    5.Sole Voting Power: -0-
    6.
    Shared Voting Power: 2,786,924 Ordinary Shares, €0.05 nominal value per share ("Ordinary Shares")(1)(2)
    7.Sole Dispositive Power: -0-
    8.
    Shared Dispositive Power: 2,786,924 Ordinary Shares(1)
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person: 2,786,924 Ordinary Shares are beneficially owned by Pfizer Inc.(1)
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares
    (See Instructions)
    ☐
    11.
    Percent of Class Represented by Amount in Row (9): 3.89%(1)(2)
    12.Type of Reporting Person (See Instructions): CO
     
     
    (1) Amount consists of 2,786,924 Ordinary Shares held by Pfizer OTC B.V. (“Pfizer OTC”). Pfizer Inc. (“Pfizer”) may be deemed to have beneficial ownership over such shares since Pfizer OTC is an indirect wholly-owned subsidiary of Pfizer.

    (2) Based on 71,583,768 outstanding Ordinary Shares, consisting of 55,583,768 Ordinary Shares outstanding as of September 30, 2023 reported in the issuer’s report on Form 6-K filed with the U.S. Securities and Exchange Commission on November 6, 2023 plus 16,000,000 Ordinary Shares issued on November 6, 2023 pursuant to an investment agreement, as reported in the issuer’s report on Form 6-K filed with the U.S. Securities and Exchange Commission on November 9, 2023.


    Page 2 of 6

    CUSIP No. 15117K103

    1.
    Names of Reporting Persons. Pfizer OTC B. V.
    I.R.S. Identification Nos. of Above Persons (entities only) N/A
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)
    ☐
    (b) |X|
    3.SEC Use Only
    4.Citizenship or Place of Organization: Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON WITH:
    5.Sole Voting Power: -0-
    6.
    Shared Voting Power: 2,786,924 Ordinary Shares, €0.05 nominal value per share ("Ordinary Shares")(1)(2)
    7.Sole Dispositive Power: -0-
    8.
    Shared Dispositive Power: 2,786,924 Ordinary Shares(1)
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person: 2,786,924 Ordinary Shares are beneficially owned by Pfizer Inc.(1)
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares
    (See Instructions)
    ☐
    11.
    Percent of Class Represented by Amount in Row (9): 3.89%(1)(2)
    12.Type of Reporting Person (See Instructions): CO
     
     
    (1) Amount consists of 2,786,924 Ordinary Shares held by Pfizer OTC. Pfizer may be deemed to have beneficial ownership over such shares since Pfizer OTC is an indirect wholly-owned subsidiary of Pfizer.

    (2) Based on 71,583,768 outstanding Ordinary Shares, consisting of 55,583,768 Ordinary Shares outstanding as of September 30, 2023 reported in the issuer’s report on Form 6-K filed with the U.S. Securities and Exchange Commission on November 6, 2023 plus 16,000,000 Ordinary Shares issued on November 6, 2023 pursuant to an investment agreement, as reported in the issuer’s report on Form 6-K filed with the U.S. Securities and Exchange Commission on November 9, 2023.


    Page 3 of 6

    CUSIP No. 15117K103

    ITEM 1.
    (A) NAME OF ISSUER:
    CELLECTIS S.A.

    (B) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICE:
    8, rue de la Croix Jarry
    75013 Paris, France
     

    ITEM 2.
    (A) NAME OF PERSONS FILING:
    This statement is being filed by Pfizer Inc., a Delaware corporation ("Pfizer") and Pfizer OTC B. V., a Netherlands private company ("Pfizer  OTC"). Pfizer  OTC is an indirect wholly-owned subsidiary of Pfizer.

    (B) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR IF NONE, RESIDENCE:
    The principal address of Pfizer is 66 Hudson Boulevard East, New York, New York 10001. 
    The principal address of  Pfizer OTC is Rivium Westlaan 142, 2909 LD Capelle aan den IJssel, Netherlands.

    (C) CITIZENSHIP:
    The citizenship or place of organization of Pfizer is Delaware and of Pfizer OTC is the Netherlands.

    (D) TITLE OF CLASS OF SECURITIES:
    Ordinary Shares

    (E) CUSIP NUMBER:
    15117K103
     
    ITEM 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable.
    (a)
    ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78os).
    (b)
    ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)
    ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)
    ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
    (f )
    ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
    (g)
    ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
    (h)
    ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)
    ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)
    ☐ A non-US institution, in accordance with §240.13d-1(b)(1)(ii)(J);
    (k)
    ☐ Group, in accordance with §230.405 240.13d-1(b)(1)(ii)(K).

    If filing as a non-US institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not applicable.

    ITEM 4. OWNERSHIP.  
    The information requested in this item is incorporated herein by reference to the cover page to this Schedule 13G.


    Page 4 of 6

    CUSIP No. 15117K103

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following |X|.

    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
    Not applicable.

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
    Not applicable.

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
    Not applicable.

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP
    Not applicable.

    ITEM 10. CERTIFICATION 

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are being held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     
     


    Page 5 of 6

    CUSIP No. 15117K103


     Signature


    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2024

    PFIZER INC.

    By: /s/ Susan Grant
    Name: Susan Grant
    Title: Assistant Secretary

    PFIZER OTC B. V.

    By:
    /s/ Eduard Slijkoord
    Name: Eduard Slijkoord
    Title: Managing Director
     


    Page 6 of 6
    Get the next $CLLS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLLS

    DatePrice TargetRatingAnalyst
    3/17/2023$6.00Buy
    Bryan Garnier
    5/18/2022$10.00Neutral → Outperform
    Robert W. Baird
    1/6/2022$16.00Overweight → Equal-Weight
    Wells Fargo
    11/30/2021$20.00Mkt Outperform
    JMP Securities
    11/8/2021Outperform → Mkt Perform
    William Blair
    10/8/2021$39.00 → $10.00Outperform → Neutral
    Baird
    10/8/2021$39.00 → $10.00Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $CLLS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cellectis to Report First Quarter Financial Results on May 12, 2025

      NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market. The press release will be available in the Investors section of Cellectis' website: https://www.cellectis.com/en/investors/press-releases/ Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at [email protected]      About Cellectis  Ce

      5/6/25 4:30:00 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting

      NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils research data on TALEN®-mediated non-viral transgene insertion for advancing cellular and gene therapies, and advancements in genetic editing using TALE base editors (TALEB), at the Society of Gene and Cell Therapy (ASGCT) annual meeting, that will be held on May 13-17, 2025 in New Orleans. The data are presented in two posters: Title: TALEN®- Mediated non-viral Transgene Insertion for the Advancement of Cellular and Gene Therapies. Cell and gene therapy approa

      4/28/25 4:30:00 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

      ○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL. ○ UCART20x22 Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025. ○ AstraZeneca partnership: R&D activities ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorder. ○ Cash position of $264 million as of December 31, 20241 provides runway in

      3/13/25 6:07:50 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Cellectis S.A. (Amendment)

      SC 13D/A - Cellectis S.A. (0001627281) (Subject)

      5/21/24 4:19:05 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cellectis S.A. (Amendment)

      SC 13G/A - Cellectis S.A. (0001627281) (Subject)

      2/14/24 5:07:22 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cellectis S.A. (Amendment)

      SC 13G/A - Cellectis S.A. (0001627281) (Subject)

      2/14/24 2:24:22 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bryan Garnier initiated coverage on Cellectis with a new price target

      Bryan Garnier initiated coverage of Cellectis with a rating of Buy and set a new price target of $6.00

      3/17/23 9:01:09 AM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectis upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded Cellectis from Neutral to Outperform and set a new price target of $10.00

      5/18/22 7:11:44 AM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectis downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Cellectis from Overweight to Equal-Weight and set a new price target of $16.00

      1/6/22 5:50:31 AM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLLS
    SEC Filings

    See more
    • SEC Form 6-K filed by Cellectis S.A.

      6-K - Cellectis S.A. (0001627281) (Filer)

      5/6/25 4:35:08 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Cellectis S.A.

      6-K - Cellectis S.A. (0001627281) (Filer)

      4/28/25 4:35:06 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Cellectis S.A.

      6-K - Cellectis S.A. (0001627281) (Filer)

      3/31/25 5:00:03 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLLS
    Financials

    Live finance-specific insights

    See more
    • Cellectis to Report First Quarter Financial Results on May 12, 2025

      NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market. The press release will be available in the Investors section of Cellectis' website: https://www.cellectis.com/en/investors/press-releases/ Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at [email protected]      About Cellectis  Ce

      5/6/25 4:30:00 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

      ○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL. ○ UCART20x22 Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025. ○ AstraZeneca partnership: R&D activities ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorder. ○ Cash position of $264 million as of December 31, 20241 provides runway in

      3/13/25 6:07:50 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025

      NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2024 ending December 31, 2024 on Thursday, March 13, 2025 after the close of the US market. The publication will be followed by an investor conference call and webcast on Friday, March 14, 2025, at 8:00 AM ET / 1:00 PM CET. The call will include the Company's fourth quarter and full year 2024 results and an update on business activities. Details for the call are as follows: Di

      3/7/25 4:30:00 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLLS
    Leadership Updates

    Live Leadership Updates

    See more
    • Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

      EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

      1/28/25 8:00:00 AM ET
      $CBUS
      $CLLS
      $MGX
      $CLXT
      Agricultural Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

      UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderAppointed Adrian Kilcoyne, M.D., MPH, MBA, an industry leader in the advancement of cell therapy treatment, as Chief Medical OfficerCash position of $264 million as of September 30, 20241; cash runway projection into 2027Conference call scheduled for 8:00 am ET / 2:00 pm CET on November 5, 2024 NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company

      11/4/24 4:30:00 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

      NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Dr. Adrian Kilcoyne, M.D., MPH, MBA as its Chief Medical Officer, effective immediately. "We're thrilled to welcome Dr. Kilcoyne to Cellectis. He is a strategic, forward-thinking drug developer who is passionate about delivering life-saving therapies to patients. His clinical vision and proven leadership, as well as his extensive experience, will strengthen our clinical development efforts as we advance our product pipeline of next-generation

      8/7/24 2:00:00 AM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care